/ Print /

IN THE PIPELINE

New biosimilar for RA to save millionsFDA’s approval of a new biosimilar—the third FDA-approved biosimilar—stands to save the US healthcare system millions of dollars.
Abuse-deterrent opioid pain drug approvedFDA recently approved the only oxycodone with oral abuse-deterrent features.
Cheaper generic EpiPen doesn't quiet criticsDespite offering a generic version of its EpiPen, Mylan has been unable to curb the backlash that began in late August over the cost of its epinephrine injection.
Health costs rise for diabetes patientsHealthcare spending for people with diabetes rose nearly 6% in 2014, according to a new study. Find out what contributed to the rise.
Diabetes increases risk of heart attack by halfUK study: Diabetes increases risk of heart attack death. Here are the surprising details.
EpiPen discounts offered after pricing flapAfter protests by patients, parents and Congressional representatives, Mylan said it would offer discounts on its epinephrine EpiPen Auto-Injector treatment to stop allergic reactions.
Game-changing depression drug on horizon
Game-changing depression drug on horizonFDA recently granted Breakthrough Therapy Designation for esketamine (Janssen Research & Development), an investigational medication to treat major depressive disorder with imminent risk for suicide.
Are PCSK9 inhibitors too pricey?
Are PCSK9 inhibitors too pricey?PCSK9 inhibitors such as alirocumab (Praluent, Sanofi) and evolocumab (Repatha, Amgen) are priced too high to benefit the US healthcare system, according to a new study.
New drug approved for chemotherapy nauseaFDA recently approved granisetron (Sustol, Heron Therapeutics) extended-release injection to prevent nausea and vomiting associated with repeat courses of chemotherapy.
AbbVie hep C drug combo enters marketIn an era when legislators, pharmacy benefit managers and others continue to protest the high cost of hepatitis C drugs, new drugs to treat the disease are welcomed. FDA recently approved ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets (Viekira XR, AbbVie) to treat patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection, including those with cirrhosis. AbbVie already markets Viekira Pak, which competes with Harvoni and Sovaldi (Gilead Sciences).